Siemens Opens Molecular Imaging Biomarker Production Centers

 

June 16, 2008

June 16, 2008 - To help ensure that more healthcare facilities throughout the U.S. have access to the positron emission tomography-computed tomography (PET-CT) technology that helps clinicians diagnose and treat disease earlier and more effectively, Siemens has opened two new radiopharmacies in Las Vegas and Pittsburgh.

These two new facilities will produce imaging biomarkers that are a crucial component of PET-CT tests used to diagnose cancer and cardiac and neurological ailments.

PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc., operates the largest PET radiopharmacy network with 50 radiopharmacies and distribution centers in the U.S., Korea and the United Kingdom that produce and distribute PET radiopharmaceuticals to hospitals, clinics and research facilities for PET imaging. The new facilities produce and supply the required radiopharmaceuticals to area hospitals that have PET-CT, which will help ease the burden of healthcare providers to produce their own radiopharmaceuticals.

The Las Vegas facility, which opened in April 2008, will manufacture fluorodeoxyglucose (FDG), the imaging biomarker used to assist with diagnosis and staging of disease processes and to monitor cellular response to treatments, such as chemotherapy and radiotherapy. The new Pittsburgh facility uses a Siemens Eclipse HP Cyclotron to produce FDG.

For more information: www.usa.siemens.com/medical